# Epidemiology of Lupus: Longitudinal Studies in Population-Based Cohorts

Source: https://welltoldgrants.com/grants/rfa-dp-22-002-epidemiology-of-lupus-longitudinal-studies-in-population/  
Official notice: https://www.grants.gov/search-results-detail/334360

> Centers for Disease Control and Prevention - ERA offered grants of up to $900,000 (at least $870,000) to any type of organization. It expected to make about 6 awards worth $26.4 million in total. Applications closed on January 19, 2022.

| Field | Value |
|---|---|
| Opportunity number | RFA-DP-22-002 |
| Agency | Centers for Disease Control and Prevention - ERA |
| Status | Forecast |
| Deadline | January 19, 2022 |
| Award ceiling | $900,000 |
| Award floor | $870,000 |
| Expected awards | 6 |
| Total funding | $26.4 million |
| Cost sharing | not required |
| Assistance Listings | 93.068 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Special Eligibility. For an application to be considered, the application must be responsive to these Special Eligibility Requirements. If your application is incomplete or non-responsive to the special eligibility requirements listed in this section, it will not enter into the review process. Component A: Epidemiology of Lupus Among the Adults Applicants must have access to an existing and established baseline cohort of lupus patients that has been followed for at least 5 years. The sample size of the cohort to be used for this study should include a minimum of 400 lupus participants. If an applicant requests a funding amount greater than the ceiling of $900,000 (Section II. Award Information) for either Component (A or B) as indicated in Section II of this NOFO, HHS/CDC will consider the application non-responsive, and it will not enter into the review process. HHS/CDC will notify the applicant that the application did not meet the submission requirement. Component B: Epidemiology of Lupus in the Pediatric Population Applicants must have access to an existing and established baseline cohort of lupus patients that has been followed for at least 3 years. The sample size of the cohort to be used for this study should include a minimum of 400 lupus participants. If an applicant requests a funding amount greater than the ceiling of $900,000 (Section II. Award Information) for either Component (A or B) as indicated in Section II of this NOFO, HHS/CDC will consider the application non-responsive, and it will not enter into the review process. HHS/CDC will notify the applicant that the application did not meet the submission requirement.

## What the grant funds

The primary purpose of this opportunity is to fund applicants with existing access to adult lupus patient populations and can extend current knowledge over 12-17 years from baseline. A second component of this funding opportunity will focus on the pediatric lupus - to advance existing knowledge of lupus in pediatric populations using an existing cohort of lupus patients. Because lupus is a rare condition, it is efficient to obtain new information from existing relevant cohorts with lupus. The research objectives among both adult and pediatric populations are to: Examine the treatment (e.g., medications including opioid; type; appropriateness; etc.) of people with lupus. Determine health care access and gaps that people with lupus experience in addressing their varied health problems (e.g., general health problems as well as those for specific lupus outcomes, such as nephritis; transitions to adulthood). Determine longer term natural history (severity, chronic pain, progression, morbidity, mortality, disability and quality of life, work/ school/activity interference, etc.) of people with lupus, including assessing potential genetic factors. Examine other factors related to disparities in lupus outcomes (e.g., age, sex, and race/ethnic group). Examine lupus comorbidities.

## Questions people ask

### Is RFA-DP-22-002 still open?

No. It closed on January 19, 2022. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.

### Who can apply for Epidemiology of Lupus: Longitudinal Studies in Population-Based Cohorts?

Centers for Disease Control and Prevention - ERA accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Epidemiology of Lupus: Longitudinal Studies in Population-Based Cohorts?

Closed January 19, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $900,000 each. About $26.4 million in total across about 6 awards.

### Who has won Chronic Diseases:  Research, Control, and Prevention   grants before?

The largest recipients over five fiscal years were New York University, American College of Rheumatology, Inc, Lupus Foundation of America Inc. The program made 88 awards worth $57.3 million in that time.